Login to Your Account



Anacor Gets $22M Up Front In Boron Deal With GSK

By Trista Morrison


Tuesday, October 9, 2007
While waiting to price its initial public offering, Anacor Pharmaceuticals Inc. signed a deal with GlaxoSmithKline plc for the discovery, development and commercialization of small-molecule, boron-based antivirals and antibacterials. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription